Details of the Drug

General Information of Drug (ID: DMKW0U6)

Drug Name

GT0918

Synonyms

KCBJGVDOSBKVKP-UHFFFAOYSA-N; UNII-QX6O64GP40; QX6O64GP40; 1398046-21-3; GT-0918; SCHEMBL12494226; 4-(4,4-Dimethyl-3-(6-(3-(2-oxazolyl)propyl)-3-pyridinyl)-5-oxo-2-thioxo-1-imidazolidinyl)-3-fluoro-2-(trifluoromethyl)-benzonitrile

Indication

Disease Entry	ICD 11	Status	REF
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 3	[1]
Prostate cancer	2C82.0	Phase 1/2	[2]
------------------------------------------------------------------------------------

Structure

3D MOL

2D MOL

Chemical Identifiers

Formula: C24H19F4N5O2S
Canonical SMILES: CC1(C(=O)N(C(=S)N1C2=CN=C(C=C2)CCCC3=NC=CO3)C4=C(C(=C(C=C4)C#N)C(F)(F)F)F)C
InChI: 1S/C24H19F4N5O2S/c1-23(2)21(34)32(17-9-6-14(12-29)19(20(17)25)24(26,27)28)22(36)33(23)16-8-7-15(31-13-16)4-3-5-18-30-10-11-35-18/h6-11,13H,3-5H2,1-2H3
InChIKey: KCBJGVDOSBKVKP-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 60194102
CAS Number: 1398046-21-3
TTD ID: D05FCR

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

References

1	ClinicalTrials.gov (NCT04728802) Proxalutamide Treatment for Hospitalized COVID-19 Patients. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)